Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742640/
https://www.ncbi.nlm.nih.gov/pubmed/34582105
http://dx.doi.org/10.1111/cts.13149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742640/
https://www.ncbi.nlm.nih.gov/pubmed/34582105
http://dx.doi.org/10.1111/cts.13149

Ejemplares similares